Recently, artemisinin derivatives have been shown to be efficacious in chemoprophylaxis of and chemotherapy for Schistosoma japonicum and S. mansoni infections. Therefore, a doubleblind, randomized, placebo-controlled study was carried out to investigate the efficacy and tolerability of artesunate plus placebo and the combination of artesunate and praziquantel in the treatment of S. haematobium infections in Gabon. The 300 infected schoolchildren included in the study were randomized to receive artesunate plus placebo ( ), praziquantel plus n p 90 placebo ( ), artesunate and praziquantel ( ), or only placebo ( ). End points n p 90 n p 90 n p 30 were efficacy, assessed as cure on day 56, and tolerability. All treatment regimens were well tolerated. The praziquantel plus placebo-treated group attained a cure rate of 73%, artesunate plus placebo a rate of 27%, the combination of artesunate and praziquantel a rate of 81%, and placebo alone a rate of 20%. In summary, earlier findings of efficacy of artemisinin derivitives against S. mansoni and S. japonicum could not be confirmed in S. haematobium infections.
Notwithstanding the efforts made to control schistosomiasis in endemic areas, the global incidence of the disease is still increasing. Chemotherapy with praziquantel is the mainstay of schistosomiasis control. Reports of in vitro resistance of Schistosoma mansoni to praziquantel have not been convincingly confirmed in vivo but are, nevertheless, alarming [1] . The situation is further complicated because the 2 other drugs for the treatment of schistosomiasis either are no longer available (metrifonate) or are not effective against all species of schistosomes (metrifonate and oxamniquine).
Animal experiments showed the efficacy of artesunate, an artemisinin derivative, in curing and preventing schistosomal infections [2] . A clinical trial in Senegal showed the efficacy and safety of artesunate for the treatment of S. mansoni infections [3] . Trials in China and in Cô te d'Ivoire demonstrated that artemether, another artemisinin derivitive, also is effective and well tolerated for the chemoprophylaxis of S. japonicum [4] and S. mansoni [5] . Furthermore, animal models of schistosomiasis indicate that the combination of an artemisinin derivative and praziquantel might act synergistically [6] .
Several studies have failed to reach high cure rates with single or repeated doses of praziquantel [7] . Praziquantel is primarily active against the adult worm stages, and it has been suggested that praziquantel fails to clear prepatent infection. Artemisinin derivatives are effective mainly against juvenile parasite stages in animal models [8] . The combination of both drugs, therefore, has the potential to increase cure rates, especially in areas with high transmission.
Artesunate has been widely used for years with great success for the treatment of malaria, and its combination with other drugs has been strongly promoted by the World Health Organization (WHO) in sub-Saharan Africa because of high efficacy and excellent tolerability [9] . The effect of artesunate against S. haematobium infections remains to be determined, and, consequently, the present study uses the same dosage of artesunate as that used in the WHO-coordinated studies for the treatment of uncomplicated falciparum malaria.
Methods
Area and population. The study was carried out between October 2000 and February 2001 in 3 villages, Bindo, Tsouké, and Nombakélé, in the province Moyen-Ogooué, Gabon. The transmission rate of S. haematobium in the area is high, with infections reaching prevalences of 80% in schoolchildren [10] . Malaria also is highly endemic.
Study design and sample size calculation. The trial was designed as a randomized, double-blind, placebo-controlled study to eval- uate the efficacy and tolerability of oral artesunate and the combination of oral artesunate and praziquantel in the treatment of asymptomatic S. haematobium infections in children aged 5-13 years. The primary end points were the cure rates after 8 weeks and the incidence of adverse events up to 7 days after the start of treatment. Cure was defined as 2 negative egg counts on 2 consecutive days. For sample-size calculation, we estimated cure rates of 70% in the praziquantel group [7, 11] and 20% in the placebo group. Therefore, 82 individuals per active substance group and 19 individuals in the placebo group were required to detect a significant difference of 20% between the treatment groups at a corrected 2-tailed !2% significance level with 80% power. To allow for losses in follow-up, 90 children per active substance group and 30 children in the placebo group were needed; thus, 300 children were included. Drugs and randomization. Artesunate, formulated as 50-mg tablets, and artesunate placebo tablets were provided by Sanofi. Praziquantel, formulated as 600-mg tablets, was supplied by Medochemie. The 4 groups received the following treatment: (i) praziquantel (40 mg/kg once; rounded to the nearest half) and artesunate placebo (over 3 days); (ii) praziquantel placebo (once) and artesunate (4 mg/kg/day, given once per day over 3 days; rounded to the nearest half); (iii) praziquantel (40 mg/kg once) and artesunate (4 mg/kg/day over 3 days); or (iv) artesunate placebo (over 3 days) and praziquantel placebo (once). The randomization code was generated by computer. The study drugs were prepared in plastic bags, which were labeled sequentially with treatment numbers according to the randomization code. Praziquantel placebo and artesunate placebo were identical in appearance to the respective active substance tablets. If patients vomited or spat out study drugs within the first hour after administration, the full doses were readministered. Treatment was supervised on all study days.
Study flow. After informed consent was obtained, the screening of the schoolchildren started with the examination of their urine for the presence of schistosome eggs. Children with positive test results subsequently underwent further examination, including a thick blood smear and hemoglobin level analysis, to assess their general health status. Exclusion criteria were symptomatic schistosomiasis, recent adequate treatment for schistosomiasis, serious underlying diseases, pregnancy or lactation, and hemoglobin level !7 g/dL. Before the first dose on study day 0, a second urine sample was obtained. Children were then assigned sequentially to treatment numbers. Changes in their condition, compared with baseline, were recorded as adverse events on days 1, 2, and 7.
The final parasitological assessment was done at day 56 on 2 consecutive days. Again, hemoglobin was measured, and a thick blood smear was prepared. Children infected with S. haematobium and/or Plasmodium falciparum were treated with single doses of praziquantel and/or sulfadoxine-pyrimethamine, respectively.
Laboratory. For the detection of schistosome eggs, the urine was analyzed by passing 10 mL of urine through polycarbonate filters (Millipore), subsequent staining with trypan blue, and counting of eggs by light microscopy, using a magnification of ϫ100. Reagent strips (Roche) were used for the semiquantitative assessment of hematuria, leucocyturia, and proteinuria. Blood hemoglobin was measured with a portable photometric analyzer (DHT Hb 523; Developing Health Technologies).
Statistical evaluation. Cure rates were expressed as percentages of all patients who had 2 negative egg counts at study end. The reduction in intensity of infection was quantified by using the decadic logarithm of the egg count reduction rate (ERR log ). The egg reduction rate (ERR) was calculated by normalizing the mean egg count of treatment failures to the mean egg count at admission. The Tukey-Kramer test was used to assess differences among the means of treatment groups. A multiple logistic regression model was used to assess the impact of variables and their interaction on the outcome (cure or failure). The model accounted for the following factors: (i) treatment with artesunate, (ii) treatment with praziquantel, (iii) interaction between both treatments, (iv) decadic logarithm of the mean egg count (LEC) before treatment, (v) interactions between LEC and treatment, (vi) village, and (vii) age. Changes in laboratory values were assessed with the paired t test for normally distributed data and with the Wilcoxon signed-rank test for nonparametric data. Proportions were tested with Pearson's x 2 test, and exact binomial confidence intervals were calculated.
Results

Screening and treatment.
Of 725 schoolchildren screened, 310 were infected with S. haematobium only, 18 had mixed infections of S. haematobium and S. intercalatum, and 1 had a mixed in- fection of S. haematobium and S. mansoni. Twenty-nine patients were not eligible (23 were lost to follow-up, 3 had S. intercalatum monoinfections, 2 did not meet the age range, and 1 had a serious underlying disease). Three hundred children who met all inclusion criteria and had asymptomatic S. haematobium infections were randomly assigned to the treatment regimens. Table 1 summarizes the demographic, clinical, and laboratory characteristics at baseline. All participants but one received the full course of the study regimen; in the single exception, the treatment was given only on day 0 and day 1, and the child was therefore excluded. Another child was mistakenly given the wrong treatment and also was excluded on study day 1. All baseline characteristics of the treatment groups were similar, and no statistical difference at the 5% significance level could be detected. Two children were lost to follow-up until day 56.
Efficacy. In total, 296 children were evaluable for the per protocol analysis (table 2) . At study end, a significant difference ( ) was seen in the cure rates: 73% with praziquantel P ! .0001 plus placebo (95% confidence interval [CI], 64%-82%), 27% with artesunate plus placebo (95% CI, 18%-36%), 81% with the combination of praziquantel and artesunate (95% CI, 72%-89%), and 20% with placebo (95% CI, 5%-35%). Treatment with artesunate did not improve the cure rate, compared with placebo ( ). Correspondingly, in children with pos-P p .45 itive test results, the reduction in severity of infection was significantly greater in the praziquantel plus placebo group (ERR log , 1.2; 95% CI, 0.7-1.7) and in the combination group (ERR log , 1.9; 95% CI, 1.4-2.4) than in the artesunate plus placebo group (ERR log , 0.7; 95% CI, 0.3-0.6) or the placebo group (ERR log , 0.4; 95% CI, 0.1-0.6). Treatment with artesunate plus placebo did not reduce the egg count, compared with placebo alone, at the 5% significance level, whereas the combination of artesunate with praziquantel improved the ERR log value significantly ( ), compared with praziquantel plus placebo. P ! .05 The rate of positive urine test results for erythrocytes at study end was lower in both groups that received praziquantel (28% and 29%, respectively; ) than in the groups that re-P ! .0001 ceived artesunate plus placebo and placebo alone (65% and 53%, respectively).
As expected, artesunate reduced the rate of infection with P. falciparum, compared with praziquantel and placebo (table 2). The combined figure for all patients who received artesunate is 28%, versus 52% for the patients who had not received artesunate ( ). P ! .0001 Logistic regression model. In the multiple logistic regression model, treatment with praziquantel and the LEC at baseline were the only variables with significant positive (praziquantel;
) or negative (LEC; ) effects on the cure rate. P p .021 P ! .0001 The interaction between artesunate and praziquantel was negative, indicating an antagonistic relation. However, this interaction lacked significance ( ). P p .47 Tolerability. All treatment regimens were well tolerated. During the study, 6 moderate and 127 mild adverse events were reported. The overall number of adverse events, as well as particular adverse events, was similarly distributed among the treatment regimens. The most frequently occurring adverse events were abdominal pain (overall, 14%) and headache (12%).
Discussion
Praziquantel is currently the standard drug for the treatment of S. haematobium infections in Gabon, but its use is limited by a cure rate well below 90%. An alternative, artesunate, has been proposed, because it has been shown to be effective in chemotherapy for S. mansoni [3] , and another artemisinin derivitive, artemether, has been found to be effective in chemoprophylaxis of S. japonicum and S. mansoni [4, 5] .
The current study failed to extend these encouraging findings to S. haematobium infections, with a cure rate of 27% in the artesunate group, compared with a 20% cure rate with placebo, although we used the same total dose administered in a previous study as chemotherapy for S. mansoni infections [3] . In addition, the combination of artesunate with praziquantel could not improve cure rates significantly, compared with treatment with praziquantel plus placebo (81% vs. 73%;
). The P p .23 cure rate reached with praziquantel plus placebo fits well to previous study results in the same area [11] . The 20% cure rate with placebo is probably due to the day-to-day variations in egg counts [11] . The relevance of the somewhat higher egg reduction rate found with the combination versus praziquantel plus placebo is not clear (ERR log , 1.9 vs. 1.2). However, the activity of the artesunate used in this study has been proven by an important reduction in the rate of P. falciparum infections 8 weeks after treatment in the 2 groups combined that received artesunate, compared with the praziquantel plus placebo and placebo only groups combined (28% vs. 52%;
). P ! .0001 Several reasons might account for the observed difference in the efficacy of artesunate therapy between S. japonicum and S. mansoni, on the one hand, and S. haematobium on the other hand. No published data exist on the efficacy of artemisinin or a derivative in vitro or in an animal infected with S. haematobium. Consequently, natural resistance of S. haematobium against artemisinin or derivatives seems to represent the most convincing conclusion derived from the present study. As shown earlier for oxamniquine, which is effective in S. mansoni but not in S. japonicum or S. haematobium infection, and for metrifonate, with efficacy against S. haematobium infection but not against S. mansoni or S. japonicum, species-specific mechanisms, including receptor-drug interactions, may play a crucial role [12, 13] .
In summary, the results of the present study clearly underline the importance of a continued effort toward the development of new drugs for the treatment of schistosomiasis.
